OnKure Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$59.5MTTM through 30 Jun 2026
Free Cash Flow -$47.9MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
-8.2%ROE
-7.7%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio32.45x
Net Debt-$192.1Mnet cash position
Cash & Equivalents$166.5M
Quality Metrics
Altman Z-Score8.45
Piotroski F-Score2 / 9
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2024: $0
Diluted EPS-$3.03TTMFY2025: $-4.40
Dividend
No dividend
Capital Allocation
R&D Spend$47M
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.